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Background: Mucopolysaccharidosis type I (MPS I) is a genetic disease caused by the deficiency of α-L-iduronidase
(IDUA) activity. MPS I is classified into three clinical phenotypes called Hurler, Scheie, and Hurler-Scheie syndromes
according to their clinical severity. Treatments for MPS I are available. Better outcomes are associated with early
treatment, which suggests a need for newborn screening for MPS I. The goal of this study was to determine
whether measuring IDUA activity in dried blood on filter paper was effective in newborn screening for MPS I.
Methods: We conducted a newborn screening pilot program for MPS I from October 01, 2008 to April 30, 2013.
Screening involved measuring IDUA activity in dried blood spots from 35,285 newborns using a fluorometric assay.
Results: Of the 35,285 newborns screened, 19 did not pass the tests and had been noticed for a recall examination. After
completing further recheck process, 3 were recalled again for leukocyte IDUA enzyme activity testing. Two of the three
had deficient leukocyte IDUA activity. Molecular DNA analyses confirmed the diagnosis of MPS I in these two newborns.
Conclusions: It is feasible to use the IDUA enzyme assay for newborn screening. The incidence of MPS I in Taiwan
estimated from this study is about 1/17,643.
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The mucopolysaccharidoses (MPS) are a group of
inherited diseases known as lysosomal storage disorders.
Each MPS is caused by the deficiency of a different en-
zyme that catalyzes the stepwise degradation of glycosami-
noglycans (GAG; mucopolysaccharides) in lysosomes.
Mucopolysaccharidosis type I (MPS I) is inherited in an
autosomal-recessive fashion and caused by deficiency of
α-L-iduronidase (IDUA; EC 3.2.1.76) activity and progres-
sive accumulation of its substrates, partially degraded
dermatan and heparin sulfate, in lysosomes. The accumu-
lation of dermatan and heparan sulfate in lysosomes trig-
ger changes in cellular metabolism that lead to tissue and
organ damage and the signs and symptoms of MPS I. Pa-
tients with MPS I can have coarse facial features,* Correspondence: cck@ms1.mmh.org.tw
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reproduction in any medium, provided the ordevelopmental delay and decline, gibbus deformity,
hepatosplenomegaly, cardiac valve disease, umbilical and
inguinal hernias, joint restriction, upper airway complica-
tions, sleep apnea, recurrent otitis media, and premature
death. MPS I is classified into three clinical phenotypes
called Hurler, Scheie, and Hurler-Scheie syndromes
according to their clinical severity [1-3].
Treatment for MPS I involves supportive and
symptom-based treatment and disease-specific treat-
ments that address the underlying cause of the disease.
Disease-specific treatments to replace IDUA activity in-
clude laronidase enzyme replacement therapy for the
non-neurologic manifestations of MPS I patients [4-12]
and bone marrow and hematopoietic stem cell trans-
plantation for Hurler syndrome patients [13-16]. de Ru
et al. reported that enzyme replacement therapy (ERT)
can result in good clearance of GAGs from many tissues
and can significantly ameliorate several symptoms [12].
However, some of the clinical symptoms of MPS I are ir-
reversible and bone marrow and hematopoietic stem cell. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[14]. Thus, early diagnosis is crucial and positively
related to the response of MPS I patients to disease-
specific therapies. Data from siblings who began treat-
ment at different ages suggest that initiation of
laronidase treatment in infancy, before the development
of significant disease manifestations, may improve out-
come with respect to coarse facial features, musculoskel-
etal disease, cardiac valve disease [17] and brain MRI
abnormalities [18]. These results suggest that early diag-
nosis of MPS I through newborn screening may improve
the prognosis of patients with MPS I.
MPS I patients were 5.3% of the MPS patients diagnosed
in Taiwan from 1984 to 2004. A Taiwanese MPS I birth
prevalence of 0.11 per 100,000 live births was estimated
using diagnostic frequency data, population data, and a re-
view of all MPS I patient’s medical records [19]. This esti-
mated birth prevalence is lower than expected, but may
reflect undiagnosed and misdiagnosed MPS I patients. We
conducted a pilot MPS I newborn screening program in
Taiwan from October 1, 2008 through April 30, 2013. The
objectives of the study were to determine whether measur-
ing IDUA activity in dried blood on filter paper was effect-
ive in newborn screening for MPS I and to determine the
birth prevalence of MPS I in Taiwan.
Materials and methods
Dried blood spot sample preparation
Dried-blood spot (DBS) samples were prepared using
the National Committee for Clinical Laboratory Stan-
dards protocol (NCCLS standard LA4-A4), “Blood Col-
lection on Filter Paper for Neonatal Screening Program”
[20,21]. Blood samples were collected by heel puncture
on the third day of life. Drops of blood were spotted dir-
ectly on filter paper (ToYo PKU No.545, Japan), and
dried at least 4 hours at room temperature. DBS samples
were stored at 4°C in zipper-lock plastic bags. IDUA ac-
tivity was measured in two 3.2-mm-diameter disks from
each DBS. From October 1, 2008 to April 30, 2013, a
total of 35,285 samples from newborns were collected
from our hospital. DBS samples from two patients with
a confirmed diagnosis of MPS I (before and after ERT)
and 4 MPS I obligate carriers were also included in this
study. All samples were collected following written in-
formed consent.
Chemicals
All chemicals were obtained from Sigma Co., and the
substrate, 4-methylumbelliferyl-α-L-iduronide, was pur-
chased from Toronto Research Chemicals in Canada.
Control DBS filter papers
Blood collected in EDTA from normal volunteers and
pooled was used to make a normal control (C1, n = 20)and an inactivated control (C2, n = 20). Inactivated con-
trol DBS were placed in a 50°C oven for 96 hours to de-
grade IDUA activity. These control dried blood spots on
filter paper (DBFPs) were used for assay quality control.
IDUA enzyme assay
A modification of the method published by Chamoles
et al. was used [22,23]. Elution buffer contains 50 mmol/L
formate buffer (pH 2.8) and 3.57 μmol/L d-saccharic
acid-1, 4-lactone. A reaction mixture contained the elute
solution and the substrate (4-methylumbelliferyl-α-L-
iduronide) in a 2:1 ratio (v/v). One 3.2 mm disc, which
contains approximate 3.55 μL of blood was punched from
each DBS using a Wallac DBS puncher (Perkin Elmer,
Inc., USA), and placed into 96-well black microtiter plate
(F 96, Nunc, Denmark). Thirty μL of reaction mixture
(two parts elution buffer and 1 part substrate) was added
to each well. The plate was covered well with foil to avoid
influences from light, air, and humidity. The plate was in-
cubated at 37°C in an orbital shaker at 250 rpm (Medclub
Scientific CB-2201) for 20 h. One-hundred and fifty μL
of glycine-carbonate buffer (stop solution) was added to
each well and the plate was kept at room temperature
for 30 minutes to stop the reaction. The fluorescence of
the enzyme product, 4-methylumbelliferone (4-MU), was
measured by using a microplate Fluorometer (Victor 2D®
Neonatal Fluorometer, Perkin Elmer) with excitation
360 nm and emission 450 nm. The filter paper did not
need to be removed during the analysis. The fluorescence
readings were corrected for blanks, and the results were
compared with the fluorescence from a 4-MU calibration
curve. IDUA enzymatic activities were expressed as micro-
moles of substrate hydrolyzed per liter of blood per 20 h.
Calibration curve
A calibration curve was made fresh each time the test
was performed. A 50 mM 4-MU stock solution was pre-
pared in DMSO. A 0.02 μM working standard solution
was first prepared in deionized water, and diluted serially
to generate seven calibrators at concentrations of 0.02,
0.008, 0.0032, 0.00128, 0.000512, 0.0002048 μM. Water
was used as a blank. The regression analysis (r2) of the
calibration curve (fluorescence reading vs. concentra-
tions of 4-MU calibrations) was excellent (r2 = 0.991).
Results
In the study, forty samples were run and calculated for
within-run and between-run precisions (Coefficient of
Variance; CV%). All the 40 samples were run in 6 con-
secutive replicates for within-run analysis, and a dupli-
cate analysis of each sample (n = 40) was performed on 6
different days sequentially. The within-run and between-
run precisions of DBFP fluorescence enzyme assay were
9.35% and 11.99%, respectively. In order to ensure the
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in DBFP, the within-run and between-run precisions of
control DBFPs (C1 and C2) were also evaluated, which
were 7.11% and 8.57% for C1, as well as 9.16% and
8.70% for C2, respectively. The overall IDUA activities in
average of C1 and C2 were 54.48 (± 4.51) and 31.55
(± 2.92) μmol/L blood*20 h.
The reference values of IDUA activities using DBFP
fluorescence enzyme assay were 9.03 - 69.52 μmol/L
blood*20 h (Mean ± SD= 39.58 ± 15.12; n = 2173) (Figure 1),
and the samples showed a normal distribution (Kolmogo-
rov-Smimov Z = 7.703) analyzed with the SPSS for Win-
dows 11.0 program (SPSS Inc., Chicago, IL, USA)
(Figure 2). For the confirmed MPS I patients before ERT
(n = 2), the IDUA activities were both less than 5% of the
normal population, and ranged from 0.29 to 0.95 μmol/L
blood*20 h. The IDUA activities obtained from the same
patients who have received ERT by weekly infusion (n = 2)
showed significantly elevated about ten-fold increases,
ranged from 5.53 to 6.77 μmol/L blood*20 h. The IDUA ac-
tivities of the carriers who are the parents of the confirmed
MPS I patients (n = 4) were slightly reduced in concentra-
tions when comparing with the normal values, ranged from
9.40 to 19.82 μmol/L blood*20 h.
In this MPS I newborn screening project, a total of
35,285 newborns were analyzed. In those, 58 newborns
had IDUA activity less than 9.03 μmol/L blood*20 h at
the first screening test. Most of them (n = 39) were ex-
clusive and their data showed normal instead after a sec-
ond rechecked analysis with the original DBS samples.Figure 1 The reference values of IDUA activities in newborn control (
(n = 2), and the same patients received ERT.The other 19 infants did not pass the tests and had been
noticed for a recall examination. All 19 neonates
(recalled rate = 0.054%) had completed the further
rechecked process, and only three infants still had IDUA
activities in DBFP lower than 9.03 μmol/L blood*20 h.
In order to confirm the diagnosis of those subjects, a
series of tests including urine GAG quantification
(DMB/CRE ratio), urinary GAG two-dimensional elec-
trophoresis (2-D EP), leukocyte IDUA enzymatic assay,
and molecular DNA analysis had been arranged. All the
methods described previously [24,25] or from literatures
reported elsewhere [26]. The results of the above con-
firmative methods showed that 2 infants had marked de-
ficiency of IDUA activities were typical of MPS I
patients (less than 5% of the reference values, 6.8-
37.0 μmol/g protein/hr), and another that showed defin-
itely reduction in IDUA activity might be a carrier
(3.5 μmol/g protein/hr). The urinary DMB ratios of the
3 infants were all normal comparing to the reference
values of newborn (44.6 ± 23.7 mg/mmol creatinine).
The 2-D EP results showed a distinct dermatan sulfate
but a faint heparan sulfate pattern in the 2 affected in-
fants and another (carrier suspected) was normal.
The molecular DNA analysis was demonstrated on the
2 highly suspicious MPS I infants and their parents
based on the methods reported by Sun et al. [27] and
Wang et al. [28]. In the study, the PCR primer sequences
and PCR conditions were modified and listed in Table 1.
PCR products were purified and sequenced using ABI
Prism 3730 DNA sequencer (Applied Biosystems). Alln = 35,285), MPS I carriers (n = 4), confirmed MPS I patients
Figure 2 The sampling to determine the reference values of IDUA activities in newborn control showed a normal distribution
(Kolmogorov-Smimov Z = 7.703).
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identify variations. Mutations were further verified by re-
striction analysis of PCR products. Two point mutations
were identified in the infant A confined as c.303 G > A
(R105Q) that inherited from father/ c.484 G > A (R162K)
that inherited from mother. For the infant B, the point
mutations were also identified and confined as c.344 G
> T (D119Y) inherited from father/ c.99 T > G (H33Q)
from mother. All sequence changes were confirmed by
restriction enzyme testing on a second PCR product,
and the restriction enzyme tests for 4 known mutations
in both MPS I patients were listed in Table 2. Molecular
genetic testing of IDUA to determine carrier status was
performed to both parents of infant C who was highly
suspected to be an MPS I carrier.
Discussion and conclusion
The reported birth incidence of MPS I in Taiwan (0.11
per 100,000 live births) is equivalent to the prevalence
rate in UK published by Murphy et al. [29], and about
one tenth of the prevalence reported by Moore et al.
[30]. The overall incidence of MPS is estimated to be 1
in 10,000 ~ 22,500 births in Europe [1-3,31], and MPS I
is by far the relatively rare type. Nelson et al. hadpublished and estimated an incidence of 1 in 76,000 for
Hurler syndrome in Northern Ireland, which was pro-
posed to be higher than previously recorded from Lowry
and Renwick in 1971 [32,33]. Murphy et al. reported that
the birth incidence was 1 in 26,206 with a carrier fre-
quency of 1 in 81 [29], which is nearly three-fold higher
than that reported by Nelson. A more recently published
report by Scott, et al. showed a higher frequency of MPS
I (1 in 35,700) in Washington State, USA [34] which was
3-fold greater than the prevalence estimated from clin-
ical studies [31,35]. Based on the results in this study,
the actual incidence of MPS I in Taiwan is about 1 in
17,643 births, and indicates that there are approximately
10 to 12 new patients to be born each year in Taiwan.
For early detection purpose, making early diagnosis is
extremely valuable, and thus giving them early therapy
can help saving lives and preventing brain damage or
other health problems.
In the past few years, many screening methods have
been proposed for MPS I newborn screening purposes,
including immunochemistry assay [36], tandem mass
spectrometry method [37-39], and fluorescent enzymatic
assay [22,23]. In those, the developments of multiplex
assay by using tandem mass spectrometry newborn
Table 1 PCR primer sequences, amplicon length and PCR reaction temperature
Exon Primer sequence Amplicon length (bp) Annealing temperature (°C)
1 F:5′-CCGCAGTCCCGAGCAC-3′ 277 60
R:5′-GCTCCGGTCTCTGAAGCTCT-3′
2 F: 5′-CCCTCGTCTTACTGCTGCTG-3′ 401 60
R: 5′TCCCATCTGTGCCTCTGTAA-3′
3,4 F: 5′-CATACCAGGCCTTCATAGGG-3′ 708 58
R: 5′CCAACCTATCCCTTGTCACC-3′
5 F: 5′-CATCACCTTGCACCCTCC-3′ 273 60
R: 5′-CGTCTACACCTGCCCTGG-3′
6 F: 5′-CCGCTCATCCCCAGGGCAGGTGTA-3′ 301 60
R: 5′-ACAGCGGCTGAGGGCGCAGAACAC-3′
7 F: 5′-CATCTCCCTCCACAGGAAGGTG-3′ 500 60
R: 5′-GGTAGCTCAGGAAGGCATTGTC-3′
8 F: 5′-TTCCTCCCGAGACGGGACAGGCGA-3′ 437 60
R: 5′-CTCCCCTTGGTGAAGGAGTC-3′
9 F: 5′-TGGGGACTCCTTCACCAAGGGGAG-3′ 370 60
R: 5′-CAGAGCCCCAGCGGGGCCAGAGAC-3′
10 F: 5′-ATCTACGCGAGCGACGAC-3′ 470 60
R: 5′-GGTCCTCAGGGTTCTCCAG-3′
11 F: 5′-GTGTGGGTGGGAGGTGGAGCGGTG-3′ 302 60
R: 5′-AGGGAAGGGCTGTGAGGCGTCGG-3′
12 F: 5′-GCTTTTGCTGGTGCACGTGT-3′ 295 60
R: 5′-AAGTGGCCCGAGTGACCGCAT-3′
13,14 F: 5′-CCTAGGGGACATGAGATGGA-3′ 814 58
R: 5′-CGGGGTTTACCCTTGGAG-3′
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particularly the lysosomal storage diseases (LSD) is
thought to be the main stream worldwide in the future.
However, those tandem mass assays still have many ob-
stacles to overcome, such as the high-priced instrumen-
tation, unstable substrate and commercially unavailable
in part, time-consuming procedures, complexity, and
high total cost. The immunochemistry assay using DBFP
is another issue commonly used for LSD newborn
screening purposes; however, the specificity and the pur-
ity of an antibody may affect the ability between antigenTable 2 Restriction enzyme test for 4 known mutations in MP
Patients Mutation Primers
Infant A R105Q F: 5′-CCTTCTGCAGGGGGTCC
Infant A-father (exon3) R: 5′-CAAACCCTGGAACACAG
Infant A R162K F: 5′-ACCCACCTGGACGGGTA
Infant A-mother (exon4) R: 5′-TGCGCTCGCCCACCGAT
Infant B D119Y F: 5′-CATACCAGGCCTTCATA
Infant B-father (exon3) R: 5′-TGGTTCTCCCTGAGAAT
Infant B H33Q F: 5′-GAGGCCCCGCACCTGCT
Infant B-mother (exon1) R: 5′-GCTCCGGTCTCTGAAGCand antibody conjugation. Additionally, a false-negative
result may be produced due to dysfunction of the detect-
able antigen (enzyme). In this study, the determination
of IDUA activity in DBFP using fluorescence enzyme assay
is a secure method for MPS I diagnosis. The DBS fluores-
cence enzyme assay has many advantages including simple
performance, cost effectiveness, high sensitivity and high
specificity, high throughput, and limited false positive detec-
tion. A diagnostic algorithm for MPS I is provided in
Figure 3. The first or a further second testing on the original
DBFP sample is accomplished that may rule out the falseS I patients
Restriction enzyme Fragment size (bp)
ACTGT-3′ Bsr GI N: 286
M: 286 + 262 + 24GAG-3′
CCGG-3′ Apo I N: 357
M: 357 + 339 + 18GAAT-3′
GGG-3′ Bsr GI N: 251
GT-3′ M: 251 + 234 + 17
GCA-3′ N: 174
TCT-3′ Pst I M: 174 + 154 + 20
Figure 3 A diagnostic algorithm for MPS I newborn screening test.
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cluding the carriers. The cut-off points of IDUA activ-
ities in DBFP by using fluorescence enzymatic assay
were 19.82 and 9.03 μmol/L blood*20 h in the first and
second time tests, respectively. The parents of highly
suspicious infants will receive a recall notice for a sec-
ond DBFP sample collection if the result of DBS fluor-
escence enzyme assay is less than the cut-off point,
9.03 μmol/L blood*20 h. The confirmative examinations
such as leukocyte enzymatic assay and molecular DNA
analysis will be performed while the second rechecked
DBS fluorescence enzyme assay failed.
The IDUA activity detected by using DBS fluorescence
enzyme assay is adapted for the initial diagnosis of MPS
I. However, it is extremely important to guarantee the
quality of DBFP samples, including collection, transport,
and storage. According to the results published by
Chamoles et al., there were no significant changes in en-
zyme activity of DBFP samples after storage for 21 days
at 4°C or −20°C; in contrast, the IDUA activity will sig-
nificantly decrease while the DBFP samples are stored atroom temperature for the same period [21-23]. In our
study, the collection, transport, and storage of DBFP
samples all followed the requirements of the National
Committee for Clinical Laboratory Standards protocol
(NCCLS standard LA4-A4), and the quality of the DBFP
was ensured.
In summary, the fluorescent enzymatic assay has the
potential to be adopted for newborn screening of MPS I.
The method is reliable, sensitive, validated, easy to per-
form, and cost-effective in measuring IDUA activity in
DBFP when comparing with the tandem mass spectrom-
etry newborn screening method. The fluorescent enzym-
atic assay does not require an expensive instrumentation
and trained staff, and the cost per assay is about two
thirds of the tandem mass spectrometry method. The in-
cidence of MPS I in this study is about 1/17,643 that
might be overestimated due to the small sample size. In
order to screen out more suspicious subjects actively
and gauge prevalence accurately, we will continue and
extend the sample numbers cooperated with other new-
born screening centers in Taiwan.
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